Qube Research & Technologies (QRT)’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.49M	Buy	637,116 +619,645	+3,547%	+$1.6M	﹤0.01%	2316
2025 Q4	$23.6K	Sell	17,471 -39,168	-69%	-$57K	﹤0.01%	3364
2025 Q3	$85.5K	Buy	56,639 +24,526	+76%	+$36.8K	﹤0.01%	3096
2025 Q2	$37.3K	Buy	+32,113	New	+$42.4K	﹤0.01%	3194
2024 Q1	–	Sell	-50,202	Closed	-$761K	–	4945
2023 Q4	$761K	Sell	50,202 -91,186	-64%	-$1.33M	﹤0.01%	2070
2023 Q3	$2.84M	Buy	+141,388	New	+$3.59M	0.01%	1198
2022 Q2	–	Sell	-15,177	Closed	-$700K	–	3222
2022 Q1	$700K	Buy	15,177 +6,363	+72%	+$343K	0.01%	1363
2021 Q4	$741K	Sell	8,814 -620	-7%	-$48K	0.01%	1357
2021 Q3	$629K	Buy	9,434 +3,949	+72%	+$228K	0.01%	1105
2021 Q2	$292K	Buy	+5,485	New	+$294K	﹤0.01%	1598

Other funds holding ZNTL

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $273M AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Qube Research & Technologies (QRT)'s ZNTL Position: Q1 2026 in Review

Qube Research & Technologies (QRT) increased its Zentalis Pharmaceuticals (ZNTL) stake by 3,547% in Q1 2026, buying an estimated $1.6M and bringing the position to 637,116 shares worth $1.49M. The position accounts for ﹤0.01% of the portfolio, ranked #2316.

Qube Research & Technologies (QRT) first reported a position in ZNTL in Q2 2021 and has held it in 10 quarters since. The position peaked at $2.84M in Q3 2023. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

Qube Research & Technologies (QRT) held 637,116 shares of Zentalis Pharmaceuticals worth $1.49M as of Q1 2026.
Qube Research & Technologies (QRT) bought 619,645 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $1.6M.
Zentalis Pharmaceuticals made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q1 2026, its #2316 holding.
Qube Research & Technologies (QRT) first reported a position in Zentalis Pharmaceuticals in Q2 2021 and has held it in 10 quarters since.
Qube Research & Technologies (QRT)'s Zentalis Pharmaceuticals position peaked at $2.84M in Q3 2023.
102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.